Last reviewed · How we verify
Dentastat (PLATINUM)
At a glance
| Generic name | PLATINUM |
|---|---|
| Sponsor | Energique, Inc. |
| Drug class | Non-Standardized Food Allergenic Extract [EPC] |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Pain relief after dental procedures
Common side effects
Key clinical trials
- A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cance (PHASE3)
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (PHASE1,PHASE2)
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors (PHASE1,PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) (PHASE3)
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dentastat CI brief — competitive landscape report
- Dentastat updates RSS · CI watch RSS
- Energique, Inc. portfolio CI